8-K: Oscar Health Reports Q2 2025 Loss, Reaffirms 2025 Guidance

Oscar Health, Inc. announced a significant net loss and increased medical loss ratio for the second quarter of 2025, while reaffirming its full-year 2025 guidance and projecting a return to profitability in 2026.

Summary

• Total revenue for Q2 2025 increased to $2.86 billion, up from $2.22 billion in Q2 2024, primarily driven by higher membership.
• The medical loss ratio (MLR) rose to 91.1% in Q2 2025, a significant increase from 79.0% in Q2 2024, mainly due to higher average market morbidity and increased net risk adjustment transfer accrual.
• Selling, General & Administrative (SG&A) expense ratio improved to 18.7% in Q2 2025 from 19.6% in Q2 2024, attributed to lower exchange fee rates and greater fixed cost leverage.
• The company reported a loss from operations of $230.5 million in Q2 2025, a reversal from a gain of $67.8 million in Q2 2024.
• Net loss attributable to Oscar Health, Inc. was $228.4 million, or $(0.89) diluted earnings per share, in Q2 2025, compared to net income of $56.2 million, or $0.20 diluted earnings per share, in Q2 2024.
• Adjusted EBITDA was a loss of $199.4 million in Q2 2025, down from a positive Adjusted EBITDA of $104.1 million in Q2 2024.
• Total membership grew to 2,027,148 as of June 30, 2025, up from 1,580,725 as of June 30, 2024.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant financial losses across key profitability metrics (net income, operating income, Adjusted EBITDA) and a substantial increase in the medical loss ratio. While revenue and membership growth are positive, the immediate financial performance is concerning. The forward-looking statements about returning to profitability in 2026 offer some optimism but do not offset the current poor results.

Positives

• Total revenue increased significantly to $2.86 billion in Q2 2025, driven by higher membership.
• Membership grew substantially to over 2 million members as of June 30, 2025, indicating strong customer acquisition.
• The SG&A expense ratio decreased to 18.7% in Q2 2025, reflecting improved cost management through lower exchange fees and fixed cost leverage.

Negatives

• The company reported a net loss of $228.4 million in Q2 2025, a significant decline from a net income of $56.2 million in Q2 2024.
• Loss from operations was $230.5 million in Q2 2025, a substantial reversal from a gain of $67.8 million in the prior year period.
• Adjusted EBITDA turned negative, with a loss of $199.4 million in Q2 2025, compared to a positive $104.1 million in Q2 2024.
• The medical loss ratio (MLR) increased significantly to 91.1% in Q2 2025 from 79.0% in Q2 2024, indicating higher medical costs relative to premiums.

Risks

• Ability to effectively execute strategy and manage growth, including integrating strategic acquisitions.
• Challenges in retaining and expanding the member base.
• Difficulty in accurately estimating incurred medical expenses or effectively managing medical and administrative costs.
• Uncertainty regarding the ability to maintain profitability in the future.
• Potential for unanticipated results or changes to risk adjustment programs.
• Maintaining quality care delivery and good relations with brokers and providers.
• Impact of evolving federal or state laws and regulations, including changes to the Affordable Care Act (ACA) and non-renewal of enhanced Advanced Premium Tax Credits (APTCs).
• Compliance with ongoing regulatory requirements, such as capital reserve and surplus requirements.
• Changes or developments in the U.S. health insurance markets.
• Compliance with laws and standards related to handling individual information and consumer protection.
• Heightened competition in the markets served.
• Reliance on quota share reinsurance to meet capital requirements and mitigate medical claims risk.
• Potential for unfavorable outcomes from lawsuits, audits, investigations, and other third-party claims.
• Risk of data security breaches affecting information systems.
• Ability to attract and retain qualified personnel.
• Failure to detect and prevent material weaknesses or significant control deficiencies in internal financial controls.
• Adverse publicity or consequences related to the company's dual class structure or controlled company status.

Future Outlook

The company reaffirmed its updated full-year 2025 guidance across all metrics. Management believes the individual market has long-term upside and expects the market to stabilize in 2026, projecting a return to profitability in 2026. The company continues to position itself for long-term growth by building the individual market into a broader healthcare marketplace.

Management Comments

• "We believe the individual market has long-term upside and is the future of healthcare."
• "Oscar is well-positioned to manage through the market reset in 2025."
• "We believe the market will stabilize next year, and expect to return to profitability in 2026."
• "We are building the individual market into a healthcare marketplace for more consumers and businesses, and continue to position the company for long-term growth."

Industry Context

The results reflect challenges within the health insurance individual market, particularly an increase in average market morbidity impacting medical loss ratios. Despite these headwinds, the company's significant membership growth suggests continued demand for its offerings in a competitive landscape. Management's comments about a 'market reset' in 2025 and expected stabilization in 2026 indicate a broader industry adjustment period, with the company aiming to navigate this while leveraging its technology platform for long-term growth in the individual healthcare market.

Comparison to Industry Standards

• No specific comparable companies, projects, or results were mentioned in the filing to provide a direct comparison to industry standards.

Stakeholder Impact

• Shareholders: Significant net losses and negative Adjusted EBITDA will likely concern investors, potentially impacting share price negatively in the short term. However, reaffirmed guidance and a projected return to profitability in 2026 may offer long-term reassurance.
• Members: Increased membership indicates continued trust and growth in the customer base. The higher medical loss ratio could imply increased healthcare utilization or costs, which might eventually affect premiums or benefits.
• Employees: Improved SG&A expense ratio due to 'greater fixed cost leverage' could suggest efficiency gains, potentially impacting staffing or operational structures.
• Providers: Maintaining good relations with providers is highlighted as a risk, indicating ongoing importance of network management for care delivery and cost control.

Next Steps

• Host a conference call on August 6, 2025, at 8:00 a.m. (ET) to discuss financial results.
• File the Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025, with the SEC.
• Work towards market stabilization and return to profitability in 2026.
• Continue building the individual market into a healthcare marketplace for more consumers and businesses.
• Continue positioning the company for long-term growth.

Key Dates

Recommendation

The company reported substantial losses for Q2 2025, a significant deterioration from the prior year, driven by a sharply increased medical loss ratio. This indicates immediate operational challenges. However, the company also reported strong membership growth and reaffirmed its full-year 2025 guidance, with management expressing confidence in market stabilization and a return to profitability in 2026. Given the mixed signals – poor current performance but a positive future outlook and strong customer acquisition – a 'hold' recommendation is appropriate. Investors should monitor the company's progress towards its 2026 profitability target and the stabilization of its medical loss ratio.

Keywords

Health insurance, Healthcare technology, SEC filing, Financial results, Medical loss ratio, Adjusted EBITDA, Membership growth, Risk adjustment, Individual market, ACA, Q2 2025